Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Salbutamol pMDI, Advisory Letter | 25/08/2025 |  |
| Cabotegravir Patient appointment reminder card | 01/08/2024 | |
| Cabotegravir Patient educational brochure | 01/08/2024 | |
| Cabotegravir Provider checklist | 01/08/2024 | |
| Cabotegravir Provider educational brochure | 01/08/2024 | |
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Tanzania |
09/09/2023 | |
| Important safety information on Dolutegravir in Tanzania (Safety Notification_Korean label update for Dolutegravir containing products) | 01-11-2023 | |
| Important safety information on Topical Corticosteroids containing products in Tanzania | 15-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Tanzania (Initial Safety Notification Engerix-B and Myelitis_November 2023) | 17-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Tanzania (Updated Safety Notification Engerix-B and Myelitis_December 2023) | 02-01-2024 | |
Important safety information on Amoxicillin/clavulanic acid containing products - MedSafe communication regarding labelling updates |
18/12/2023 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024) |
08/01/2024 |
|
Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir |
19/03/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024 |
07/05/2024 |
|
